Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
WEBby Iqra Mumal, MSc July 8, 2019. An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.
For PAH Treatment, Mylan Launches Tadalafil Tablets, 1st Generic...
WEBAug 22, 2018 · Mylan Announces U.S. Launch of 20 mg Tadalafil Tablets, 1st Generic of Adcirca for PAH Treatment. by Iqra Mumal, MSc August 22, 2018. Mylan recently introduced a formulation of 20 mg tadalafil tablets, the first generic version of Eli Lilly ‘s Adcirca, in the United States for patients with pulmonary arterial hypertension (PAH).
CS1 receives orphan medicinal product status for PAH in Europe
WEBSep 4, 2024 · The European Commission has granted orphan medicinal product designation to Cereno Scientific ’s CS1 for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications for life-threatening or chronically debilitating diseases, affecting up to five …
Approval of new treatments for pulmonary hypertension prompts...
WEBApr 3, 2024 · First, in late March, the FDA approved a once-daily, fixed-dose tablet containing a combination of macitentan and tadalafil for adults with pulmonary arterial hypertension (PAH). It will be marketed under the brand name Opsynvi and is the first single-tablet treatment combination to become available to people with PAH in the U.S.. Then, just days later, the FDA approved the under-the-skin ...
Phaware Podcast: Steve Mathai, MD (Part 1) – Pulmonary...
WEBNov 15, 2017 · The phaware® interview (Episode 111) Dr. Stephen Mathai is an associate professor of medicine at the Johns Hopkins University School of Medicine. His areas of clinical expertise include pulmonary disease and critical care medicine. His research interests include scleroderma-associated pulmonary …
FDA approves sotatercept, now Winrevair, to treat PAH in adults
WEBMar 27, 2024 · The U.S. Food and Drug Administration (FDA) has approved the under-the-skin injection therapy sotatercept-csrk — to be marketed under the brand name Winrevair — to treat adults with pulmonary arterial hypertension (PAH). The now-approved treatment is expected to be available for dispensing by select …
Asporin may be biomarker, therapeutic target in PAH: Study
WEBby Andrea Lobo August 23, 2024. The protein asporin was identified as a possible biomarker of disease severity and to be protective in pulmonary arterial hypertension (PAH), a study suggests that used lung and blood samples from people with the disease. The protein was increased in PAH patients and correlated with reduced disease severity.
Liquidia sues FDA over exclusivity rights for United's Tyvaso DPI
WEBAug 30, 2024 · The FDA’s tentative approval of Yutrepia was based on INSPIRE (NCT03399604), a Phase 3 study showing the therapy could safely improve exercise capacity and quality of life in adults with PAH, including in those new to inhaled treprostinil or in those switching from Tyvaso (nebulized treprostinil).. United previously filed a complaint against the FDA for accepting Liquidia’s amended new ...
Opsumit for PH - Pulmonary Hypertension News
WEBNov 14, 2022 · Opsumit (macitentan), is an oral once-daily therapy used to widen the blood vessels of people with pulmonary arterial hypertension (PAH), slowing disease progression and reducing patients’ risk of being hospitalized. Opsumit is being investigated as a possible treatment for other types of pulmonary hypertension, including chronic ...
Orenitram for Pulmonary Hypertension
WEBJan 31, 2023 · Prostacyclin is a naturally occurring lipid molecule that helps the pulmonary arteries relax and widen, a process called vasodilation. It also inhibits platelet activation, preventing them from building up and blocking arteries. Orenitram’s active ingredient, treprostinil, is a synthetic version of prostacyclin.